M2-type TAMs have demonstrated the ability to activate breast cancer cells via the EGFR/PI3K/Akt pathway, resulting in the upregulation of SGLT1, a phenomenon that fosters tamoxifen resistance in cancer cells [74]. This evidence concerns the gene AKT1 and breast carcinoma.